Press Releases Overview Press Releases Investor Presentation & Events Menu Toggle Presentations Events Governance Menu Toggle Directors Leadership Committee Composition Documents & Charters Stock Information Menu Toggle Stock Quote & Chart Analyst Coverage Ownership Profile Financials & Filings Menu Toggle SEC Filings Annual Reports and Proxies Quarterly Results Investor Resources Menu Toggle Investor FAQs Email Alerts Contact IR Overview Press Releases Investor Presentation & Events Presentations Events Governance Directors Leadership Committee Composition Documents & Charters Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials & Filings SEC Filings Annual Reports and Proxies Quarterly Results Investor Resources Investor FAQs Email Alerts Contact IR Year All202620252024202320222021202020192018 May 19, 2026 Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders PDF Version May 07, 2026 Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results PDF Version May 01, 2026 Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET PDF Version April 23, 2026 Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors PDF Version April 17, 2026 Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital PDF Version March 12, 2026 Vaxart Provides Business Update and Reports Full Year 2025 Financial Results PDF Version March 03, 2026 Vaxart to Host Upcoming Conference Calls PDF Version February 18, 2026 Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 PDF Version January 15, 2026 Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants PDF Version January 08, 2026 Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 PDF Version
Year All202620252024202320222021202020192018 May 19, 2026 Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders PDF Version May 07, 2026 Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results PDF Version May 01, 2026 Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET PDF Version April 23, 2026 Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors PDF Version April 17, 2026 Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital PDF Version March 12, 2026 Vaxart Provides Business Update and Reports Full Year 2025 Financial Results PDF Version March 03, 2026 Vaxart to Host Upcoming Conference Calls PDF Version February 18, 2026 Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 PDF Version January 15, 2026 Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants PDF Version January 08, 2026 Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 PDF Version
May 19, 2026 Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders PDF Version
May 07, 2026 Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results PDF Version
April 17, 2026 Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital PDF Version
March 12, 2026 Vaxart Provides Business Update and Reports Full Year 2025 Financial Results PDF Version
February 18, 2026 Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 PDF Version
January 15, 2026 Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants PDF Version
January 08, 2026 Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 PDF Version
